Mylan and Novo Nordisk reach settlement of US patent litigation related to Ozempic

NATCO Pharma Limited announces that Mylan Pharmaceuticals nc. and Novo Nordisk have reached a settlement of the U.S. patent litigation related to generic Ozempic (Semaglutide). NATCO and Mylan are partnered on the development of generic Ozempic products. The terms of the settlement are confidential. NATCO's manufacturing partner is Stelis.

USFDA completes inspection of Alembic’s formulation facility at Panelav

Alembic Pharmaceuticals Limited has successfully completed the United States Food and Drug Administration (USFDA) inspection for its Oncology (Injectable and Oral Solid) Formulation Facility (F-2) located at Panelav. The inspection was successfully completed without any Form 483 observation. The inspection was conducted from 7 - 8 October, 2024.